The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: An open-label study

ADHD Attention Deficit and Hyperactivity Disorders

Volumn 2, Issue 2, 2010, Pages 87-92

  Gabriel, Adel ^a  

^a CALGARY HEALTH REGION   (Canada)

Author keywords

ADHD; GA comorbidity; Mixed amphetamine salts

Indexed keywords

AMPHETAMINE; CITALOPRAM; VENLAFAXINE;

ADD ON THERAPY; ADHD SELF REPORT SCALE; ADULT; AGED; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE MONITORING; CHECKLIST; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMORBIDITY; DAYTIME SOMNOLENCE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; INSOMNIA; MALE; NERVOUSNESS; OPEN STUDY; PRIORITY JOURNAL; PULSE RATE; RATING SCALE; RECOMMENDED DRUG DOSE; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SYMPTOM; SYSTOLIC BLOOD PRESSURE; WEIGHT CHANGE;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AMPHETAMINES; ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 79960045719     PISSN: 18666116     EISSN: 18666647     Source Type: Journal    
DOI: 10.1007/s12402-010-0025-z     Document Type: Article

References (29)

1. Adler L, Spencer T, Farone S, Kessler R, Howes M, Beiderman J, Secnik C (2006) Validity of pilot Adult ADHD Self Report Scale (ASRS) to rate Adult ADHD symptoms. Ann Clin Psychiatry 18(3):145-148
2. Baldwin D, Anderson I, Nutt D, Bandelow B, Bond A, Davidson J, den Boer J, Fineberg N, Knapp M, Scott J, Wittchen H (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-596
3. Barkley R, Brown T (2008) Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. CNS Spectr 13(11):977-984
4. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M (2006) Functional impairments in adults with selfreports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 67(4):524-540
5. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Michel E, Martin J, Spencer T (2007) Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/ hyperactivity disorder. BMC Psychiatry 14(7):49
6. Brown R, Amler R, Freeman W (2005) Treatment of attention deficit hyperactivity disorder: overview of evidence. Paediatrics 115:e749-e757
7. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (2008) Canadian ADHD Practice Guidelines. CADDRA, Toronto
8. Cumyn L, Kolar D, Keller A, Hechtman L (2007) Current issues and trends in the diagnosis and treatment of adults with ADHD. Expert Rev Neurother 7(10):1375-1390
9. Cumyn L, French L, Hechtman L (2009) Comorbidity in adults with attention-deficit hyperactivity disorder. Can J Psychiatry 54(10):673-683
10. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50-55
11. Henning ER, Turk CL, Mennin DS, Fresco DM, Heimberg RG (2007) Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety 24:342-349
12. Kessler R, Brandenburg N, Lane M, Roy-Byrne P, Stang P, Stein DJ, Wittchen H (2005) Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 35:1073-1082
13. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky A (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163(4):716-723
14. Klassen L, Katzman M, Chokka P (2009) Adult ADHD and its comorbidities, with a focus on bipolar disorder. J Affect Disord [Epub ahead of print]
15. McGough J, Smalley S, McCracken J, Yang M, Del'Homme M, Lynn D, Loo S (2005) Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 162(9):1621-1627
16. McIntyre RS, Konarski JZ, Mancini DA, Fulton KA, Parikh SV, Grigoriadis S, Grupp LA, Bakish D, Filteau MJ, Gorman C, Nemeroff CB, Kennedy SH (2005) Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. CMAJ 173(11):1327-1334
17. Montano B (2004) Diagnosis and treatment of ADHD in adults in primary care. J Clin Psychiatry 65(Suppl 3):18-21
18. MTA cooperative group (1999) A 14 month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder: multimodal treatment study of children with ADHD. Arch Gen Psychiatry 56:1073-1086
19. National Institute of Mental health (1970) CGI: Clinical global impression. In: Guy W, Bonato RR (eds) Manual for the ECDEU assessment battery, 2nd rev. edn. Chevy Chase, Maryland, pp P12-1-P12-6
20. Newcorn JH, Weiss M, Stein MA (2007) The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. CNS Spectr 12(8 Suppl 12):1-14 (quiz 15-16)
21. Poulton A (2006) Long-term outcome of stimulant medication in attention deficit hyperactivity disorder. Expert Rev Neurother 6:551-561
22. Ruscio A, Chiu W, Roy-Byrne P, Stang P, Stein D, Wittchen H, Kessler R (2007) Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J Anxiety Disord 21:662-676
23. Schweizer E (1995) Generalized anxiety disorder. Longitudinal course and pharmacologic treatment. Psychiatr Clin North Am 18:843-857
24. Sheehan D, Hamett-Sheehan K, Raj B (1996) The measurement of disability. Int Clin Psychopharmcol 11(Suppl 3):89-95
25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar G (1998) The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33(quiz 34-57)
26. Simon V, Czobor P, Bálint S, Mészáros A, Murai Z, Bitter I (2007) Detailed review of epidemiologic studies on adult Attention Deficit/Hyperactivity Disorder (ADHD). Psychiatr Hung 22(1):4-19
27. Sobanski E, Brüggemann D, Alm B, Kern S, Deschner M, Schubert T, Philipsen A, Rietschel M (2007) Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 257(7):371-377
28. Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R (2006) Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28(2):266-279
29. Wilens T, Biederman J, Faraone S, Martelon M, Westerberg D, Spencer T (2009) Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. J Clin Psychiatry 70(11):1557-1562